Don’t send a generic resume — generate a resume and cover letter tailored to this exact role.
Inossia AB is seeking a full-time Quality Assurance (QA) Manager based in Stockholm. The role involves managing the Quality Management System (QMS) and ensuring compliance with ISO standards. Responsibilities include overseeing product releases, conducting audits, and supporting supplier quality management.
The ideal candidate has extensive QA experience in the medical device industry, strong knowledge of ISO 13485, and proven audit experience. The company promotes a dynamic workplace that values contributions towards improving fracture treatments for osteoporotic patients.
Inossia is now recruiting a Quality Assurance (QA) Manager. The position is full‑time and based in our headquarters office in Stockholm. It is designed for a new colleague to join Inossia's team.
Inossia aims to improve fracture treatment for osteoporotic patients, providing vertebral augmentation solutions tailored to the mechanical properties of bone. The company is entering a pivotal growth phase with the launch of its first product and the transition from development to commercial operations while maintaining a commitment to ongoing research.
As a QA Manager you will manage our QMS and oversee product releases. You will lead training on new SOPs, collaborate closely with the Production Manager to ensure accurate and compliant documentation, prepare the organization for audits, and conduct supplier audits.
We are looking for someone with a can‑do attitude, strong organizational skills, and a quality‑driven mindset. You enjoy taking ownership, managing priorities, and working independently or as part of a team. You are analytical, detail‑oriented, and can effectively combine flexibility with strong decision‑making ability. You also thrive in a dynamic workplace where people matter and your contributions create a positive impact.
Inossia aims to improve fracture treatment for osteoporotic patients so that they can live an active life. We are launching our first product and transitioning to commercial operations, while continuing research to advance spine‑care solutions. We completed a clinical study of 196 patients in 4 countries and 9 clinics, and received Breakthrough Device Designation for Inossia Cement Softener in June 2025.
For more information about the position, please contact:
Krishan Johansson Haque, PhD
Sr Recruitment Consultant, QRIOS Life Science & Engineering
T: +46 (0)72-070 16 53
E: krishan.johansson-haque@qrios.se